| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN DIEGO—Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, recently published in the Journal of Visual Experiments the establishment and immunological characterization of pancreatic ductal adenocarcinoma (PDAC) orthotopic tumor homograft models.
 
PDAC research represents an area of high unmet medical need, the company says, as PDAC fails to respond to a range of cancer therapies, including immuno-oncology (IO) therapy, partially due to an abundant tumor microenvironment (TME), that protects tumor cells from treatment. The development of new therapeutic and combination strategies requires highly relevant preclinical models recapitulating the complexity of PDAC tumors including the TME.
 
The orthotopic PDAC homograft models developed in this publication are said to capture the morphology of human tumors with enriched stromal content which is more suitable for preclinical pharmacology evaluation. The publication demonstrates that the TME of orthotopic transplantation differs from common subcutaneous transplantation, and indicates that this approach could better mimic human PDAC, and be more predictive of IO treatment in patients which is also highly dependent on the TME.

Related Topics

Published In

Volume 15 - Issue 1 | January 2019

January 2019

January 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue